Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
13.65
+0.03 (0.22%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$612,700
Profits / Employee
$20,900
Market Cap
3.58B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10,000 | 0 | - |
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Amgen | 31,500 |
| Grifols | 25,247 |
OGN News
- 1 day ago - Organon opens REMS Program for Miudella - TheFly
- 1 day ago - Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability - Business Wire
- 11 days ago - Organon & Co. Quarterly report: Q2 2026 - Filings
- 11 days ago - Organon Announces Quarterly Dividend - Business Wire
- 18 days ago - Organon to present results from analysis of Phase 3 trials of VTAMA cream - TheFly
- 18 days ago - New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 - Business Wire
- 19 days ago - Organon & Co. Transcript: EGM 2026 - Transcripts
- 25 days ago - Organon & Co. Proxy statement: Proxy filing - Filings